Corrigendum: Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study

Kyunghwan Oh; Hee Seung Hong; Nam Seok Ham; Jungbok Lee; Sang Hyoung Park; Suk-Kyun Yang; Hyuk Yoon; You Sun Kim; Chang Hwan Choi; Byong Duk Ye

doi:10.5217/ir.2021.00173.e

Search: Intest Res Search

CLOSE

Intest Res > Volume 21(2); 2023 > Article

Oh, Hong, Ham, Lee, Park, Yang, Yoon, Kim, Choi, Ye, and on behalf of the Korean Association for the Study of Intestinal Diseases: Corrigendum: Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study

Corrigendum

Intestinal Research 2023;21(2):273.

Published online: April 28, 2023

DOI: https://doi.org/10.5217/ir.2021.00173.e

Corrigendum: Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study

Kyunghwan Oh¹, Hee Seung Hong¹, Nam Seok Ham¹, Jungbok Lee², Sang Hyoung Park^1,^3,⁴, Suk-Kyun Yang^1,^3,⁴, Hyuk Yoon⁵, You Sun Kim⁶, Chang Hwan Choi⁷, Byong Duk Ye^1,^3,⁴, on behalf of the Korean Association for the Study of Intestinal Diseases

¹Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

²Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

³Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

⁴Digestive Diseases Research Center, University of Ulsan College of Medicine, Seoul, Korea

⁵Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

⁶Department of Internal Medicine, Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea

⁷Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

This corrects the article "Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study" in Volume 21 on page 137.

https://doi.org/10.5217/ir.2021.00173

Intest Res 2023;21(1):137-147

In the article entitled “Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study,”1 the data on page 140 of the text were incorrectly indicated. The revised data are shown in bold.

“Corticosteroid-free clinical remission/response were achieved in 25 (51.0%)/29 (59.2%) patients at week 8 and 26 (53.1%)/34 (69.4%) patients at week 20, respectively (Fig. 2).”

REFERENCES

1. Oh K, Hong HS, Ham NS, et al. Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study. Intest Res 2023;21:137-147.

TOOLS

Download Citation

Share :

METRICS

0 Crossref
Scopus
1,181 View
134 Download

We recommend

ABOUT

ARTICLE & TOPICS

Article Category

Browse all articles >

TOPICS

Browse all articles >

BROWSE ARTICLES

EDITORIAL POLICY

AUTHOR INFORMATION

Editorial Office: Room 310, Lotte Gold Rose II, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-957-6145 Fax: +82-2-957-6146 E-mail: thekasid@irjournal.org